Use of belatacept during post depletional repopulation to facilitate tolerance in renal allograft recipients

Next Previous
Trial Profile

Use of belatacept during post depletional repopulation to facilitate tolerance in renal allograft recipients

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Belatacept (Primary) ; Sirolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 14 Nov 2017 Results published in the American Journal of Transplantation
    • 22 Dec 2015 Planned End Date changed from 1 Dec 2019 to 1 Aug 2019 as per ClinicalTrials.gov record.
    • 22 Dec 2015 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2019 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top